John Overdeck’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

John Overdeck’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-54,988	Closed	-$5.9M	–	3399
2023 Q1	$5.9M	Sell	54,988 -107,846	-66%	-$12.4M	0.02%	825
2022 Q4	$17.9M	Sell	162,834 -31,780	-16%	-$2.06M	0.06%	382
2022 Q3	$11.5M	Buy	194,614 +144,856	+291%	+$6.63M	0.04%	451
2022 Q2	$1.41M	Buy	+49,758	New	+$1.44M	﹤0.01%	1381

Other funds holding RXDX

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

John Overdeck's RXDX Position: Q2 2023 in Review

John Overdeck sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 54,988 shares — an estimated $5.9M sold.

John Overdeck first reported a position in RXDX in Q2 2022 and held it in 4 quarters. The position peaked at $17.9M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

John Overdeck reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
John Overdeck sold 54,988 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $5.9M.
John Overdeck first reported a position in Prometheus Biosciences, Inc. Common Stock in Q2 2022 and held it in 4 quarters.
John Overdeck's Prometheus Biosciences, Inc. Common Stock position peaked at $17.9M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Two Sigma Investments's 13F filing for Q2 2023, filed 14 Aug 2023.